Vaccine stocks rally on reports of U.S.-led push for cancer vaccines
Reports of a federal cancer vaccine initiative and Moderna's cancer vaccine progress lifted vaccine shares and put oncology biotechs on retail investors' radar.
Zacks Investment Research · +12 outlets
FDA approves a new weight-loss drug, drawing broad coverage
The approval adds another obesity treatment to the market amid heavy interest in GLP-1 and next-generation weight-loss therapies.
Olhar Digital · +14 outlets
Bristol Myers dips on 'confounding' lung drug results for admilparant
Only the lower of two tested doses met the main objective in idiopathic pulmonary fibrosis, raising analyst doubts about the therapy's prospects.
Biopharmadive · +3 outlets
Caribou halts allogeneic CAR T programs as funding pressures mount
The pullback underscores the financing squeeze facing developers of off-the-shelf cell therapies.
The Medicine Maker · +1 outlets
Aspen Neuroscience files to go public to fund Parkinson's cell therapy
The IPO filing is aimed at raising money for a lead program that turns a patient's own cells into dopamine-producing neurons.
Biopharmadive · +4 outlets
First Tracks climbs on 'impressive' Phase 2 celiac disease study data
Initial findings bolstered analyst views that the CD122-targeting drug could have pipeline-in-a-product potential.
Biopharmadive · +3 outlets
Paradigm shifts in pharma: $500B patent problem arrives in waves, not a cliff
Merck is most exposed near term, with AbbVie, J&J and Sanofi facing later losses, shaping dealmaking strategy.
Biopharmadive · +1 outlets
NIH's $200M cancer vaccine push gives mRNA a second act
The federally backed program signals renewed support for mRNA-based cancer vaccine research.
TrialSite News · +1 outlets
India panel to finalise cancer drugs for 30% trade margin cap, with Rs 2,500 crore savings seen
The pricing move could lower costs for cancer medicines in India if implemented.
The Economic Times · +1 outlets
EMA rejects MaaT Pharma's Xervyteg approval; company shifts to U.S. Phase 3
The European regulator's rejection redirects the microbiome therapy developer toward a U.S. late-stage trial.
scanx.trade · +4 outlets
Bausch + Lomb swaps CEOs; Merck reveals eye drug data
Brent Saunders and Bausch + Lomb mutually agreed on his exit, while Tezspire data and buyout returns drew attention.
Biopharmadive · +3 outlets
Disc Medicine stock slumps after FDA declines approval for inherited disorder drug
The FDA cited efficacy concerns in rejecting the drug for an inherited blood disorder.
Stocktwits · +1 outlets
Moleculin Biotech shares drop 25% as interim cancer trial data miss significance
The interim readout fell short of statistical significance, pressuring the company's shares.
Stocktwits · +1 outlets
FDA approves once-monthly olanzapine injection for adults with schizophrenia
The long-acting injectable adds a dosing option for schizophrenia maintenance treatment.
Drug Topics · +14 outlets
BridgeBio reports improved symptoms in Phase 3 rare-disease drug trial
The late-stage readout supports the company's rare-disease pipeline.
Seeking Alpha · +14 outlets
Eli Lilly reports high weight loss in new drug trial
The trial results add to the competitive obesity drug landscape.
Olhar Digital · +14 outlets
China's biotech playbook shifts from licensing deals to billion-dollar NewCo exits
The shift reflects evolving cross-border deal structures for Chinese drug developers.
Korea Biomedical Review
Personalized mRNA cancer vaccines near the clinic, but barriers remain
Manufacturing, cost and regulatory hurdles stand between personalized mRNA vaccines and broad use.
Genetic Literacy Project